94 reports

  • OF CONTENTS

In December 2017, the FDA approved Bristol-Myers Squibb' s PD-## inhibitor Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

  • Hepatitis
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

The offers a wide range of devices and kits for autoimmune diseases worldwide.

  • Endoscope
  • Endoscopic Device
  • World
  • Forecast
  • Smith & Nephew Plc

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • East Asia
  • Japan
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Brazil
  • South America
  • Forecast
  • Medtronic, Inc.

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Latin America
  • Mexico
  • North America
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Australasia
  • Australia
  • Oceania
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • China
  • East Asia
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • India
  • South Asia
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Italy
  • Southern Europe
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Eastern Europe
  • Russia
  • Forecast
  • Medtronic, Inc.

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • East Asia
  • South Korea
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Southern Europe
  • Spain
  • Forecast
  • Olympus Corporation
  • Commitment to innovation in technology Availability of affordable and high-quality medicines
  • OTHER PROMINENT VENDORS

About hepatitis Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases....

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

(USA) ##.

  • Antiviral
  • Hepatitis
  • United States
  • World
  • Market Shares
  • FINANCIAL

EACH PARTY, THROUGH ITS REPRESENTATIVES, SHALL HAVE ONE (##) VOTE ON THE JSC AND EACH SUBCOMMITTEE.

  • Endoscope
  • Hepatitis
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.

IFN-based therapies such as Pegintron have adverse side effects and are not recommended for use in patients with advanced liver diseases or autoimmune disorders.

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.
  • GLOBAL ANTIVIRAL DRUGS MARKET SEGMENTATION BY THERAPIES
  • GLOBAL HEPATITIS THERAPEUTICS MARKET

OTHER CAUSES INCLUDE HEAVY CONSUMPTION OF ALCOHOL, TOXINS, MEDICATIONS, AND OTHER INFECTIONS SUCH AS HIV AND AUTOIMMUNE DISEASES.

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.
  • 3.6 SOVALDI / HARVONI SALES & FORECAST

The Sovaldi/ Harvoni sales was the second biggest drugs sales in the universe just short of the US$ ##. ## Billion in sales recorded in 2014 by AbbVie' s autoimmune disease drug Humira, which is believed to be the world' s topselling pharmaceutical.

  • Hepatitis
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • PERKINELMER

IT IS THE WORLD LEADER IN IN VITRO DIAGNOSTICS AND MEDICINES FOR CANCER AND TRANSPLANTATION; IT IS ALSO ACTIVE IN SEVERAL OTHER MAJOR THERAPEUTIC AREAS INCLUDING AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, VIROLOGY, METABOLIC DISORDERS AND DISEASES OF THE CENTRAL NE

  • Hepatitis
  • China
  • Abbott Laboratories, Inc.
  • Immucor, Inc.
  • Roche Group
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • Johnson & Johnson - Discovery, 2016

Johnson & Johnson - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development...

  • Hepatitis
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Hepatitis
  • Pharmaceutical
  • Therapy
  • World
  • Shenogen Pharma Group

The presentation focused on Can-Fite' s CF## for the treatment of autoimmune and anti-inflammatory diseases.

  • Cardiovascular Drug
  • Hepatitis
  • Therapy
  • World
  • Can-Fite BioPharma Ltd.
  • R&D Progress

Reasons for premature withdrawal included patient refusal to continue or withdrew consent (## patients), disease remission (## patient) and death due to an acute infection (## patient).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • REPLICor Inc.

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.
  • R&D Progress

Reasons for premature withdrawal included patient refusal to continue or withdrew consent (## patients), disease remission (## patient) and death due to an acute infection (## patient).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • REPLICor Inc.
  • OTHER LOCATIONS & SUBSIDIARIES

Tiziana Life Sciences is developing foralumab for treatments of autoimmune and inflammatory diseases.

  • Cancer
  • Hepatitis
  • United Kingdom
  • Deals & Alliance
  • Tiziana Life Sciences PLC
  • Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer
  • Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer

Tiziana Life Sciences is developing foralumab for treatments of autoimmune and inflammatory diseases.

  • Hepatitis
  • Targeted Therapy
  • United Kingdom
  • Company
  • Tiziana Life Sciences PLC
  • SWOT Analysis - Overview

The company' s ddRNAi technology holds significant potential to address various disease conditions in the therapeutic domain of cancer (lung, liver, and breast), neurological diseases (huntingdons, dementia, and glioblastoma), infectious diseases (HIV/ AIDS, Hepati

  • Biopharmaceutical
  • Hepatitis
  • RNA Interference
  • Therapy
  • Benitec Biopharma Limited